ReviewNeurology and therapy2026
Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.
Review in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsing multiple sclerosis (RMS) is most often diagnosed in young adulthood but may also manifest during childhood or later in life. The number of older people living with RMS (pwMS) continues to grow as life expectancy increases and MS incidence rises among older adults. This review summarises the principal challenges in managing pwMS at different stages of life. Paediatric-onset RMS: RMS onset in childhood and adolescence is typically characterised by a higher relapse rate. Early diagnosis, timely intervention, and specialised care are essential. Management also requires close collaboration among healthcare providers, families, and educational institutions to help children balance the disease burden with academic, social, and family life. Young adults with RMS: In young adulthood, MS can disrupt education, employment, relationships, and family planning. Individualised treatment strategies and shared decision-making are essential to align disease management with evolving personal and professional goals. Older pwMS: Age-related issues such as immunosenescence, disability progression, comorbidities, polypharmacy, and menopause become increasingly relevant. Vaccination is particularly important given both immunomodulatory therapies and reduced immune resilience associated with immunosenescence. As pwMS age, treatment strategies may include disease-modifying therapy (DMT) de-escalation, discontinuation, or immune reconstitution therapies to reduce long-term immunosuppression. In conclusion, a holistic, pwMS-centred approach is essential to tailor MS management across the lifespan, adjusting to the medical, functional, and psychosocial needs of pwMS at each stage of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.